The complications of treating elderly patients with AML

The complications of treating elderly patients with AML

VJHemOnc

1 year
346 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are many issues surrounding the use of chemotherapy drugs in this population. In this interview, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, highlights the challenges of AML treatment in the elderly, and some of the options that can be offered to patients in which high dose chemotherapy will not prove beneficial, or patients who have a low tolerance to intensive chemotherapy. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Up Next Autoplay
JAVELIN Study: How Does This Affect Clinicians?
JAVELIN Study: How Does This Affect Clinicians?
Category: Urology
0 Views
Cancer-News 58 minutes
What happened to patients with progression of disease?
What happened to patients with progression of disease?
Category: Urology
3 Views
Cancer-News 1 hour
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Category: Urology
1 Views
Cancer-News 1 hour
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 3 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 3 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 3 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
0 Views
Cancer-News 3 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
2 Views
Cancer-News 3 days
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Category: News
1 Views
ash 3 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 4 days